Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Abpro Holdings ( (ABP) ) has issued an announcement.
On December 9, 2025, Abpro Holdings announced it received an extension from the Nasdaq Hearings Panel to regain compliance with Nasdaq listing requirements. This extension is seen as a validation of Abpro’s compliance plan, which includes a reverse stock split, a market transfer application, and a capital strategy to boost stockholders’ equity. The company has streamlined operations, reducing expenses by about 60%, and secured up to $44 million in equity financing to support its operations and strategic objectives through 2026. Abpro is advancing its lead antibody candidate, ABP-102, in partnership with Celltrion, aiming for first-in-human trials in 2026, while continuing to innovate its DiversImmune® and MultiMab™ platforms.
The most recent analyst rating on (ABP) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Abpro Holdings stock, see the ABP Stock Forecast page.
More about Abpro Holdings
Abpro Holdings, Inc. is a biotechnology company based in Burlington, Massachusetts, focused on developing next-generation antibody therapies. The company targets severe and life-threatening diseases, including HER2+ cancers, non-HER2+ gastric and liver cancer, and conditions like wet age-related macular degeneration and diabetic macular edema, using its proprietary DiversImmune® platform.
Average Trading Volume: 163,845
Technical Sentiment Signal: Sell
Current Market Cap: $15.78M
For a thorough assessment of ABP stock, go to TipRanks’ Stock Analysis page.